Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes

    Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes

    FromBreastcancer.org Podcast

    Start listeningView podcast show

    Enhertu for HER2-Low Breast Cancer: Patient-Reported Outcomes

    FromBreastcancer.org Podcast

    ratings:
    Length:
    13 minutes
    Released:
    Sep 14, 2022
    Format:
    Podcast episode

    Description

    At the European Society for Medical Oncology Congress 2022, Dr. Naoto Ueno presented patient-reported quality-of-life outcomes from the DESTINY-Breast04 study, which found that compared to doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
    Listen to the episode to her Dr. Ueno explain:

    how the researchers assessed quality of life

    the results showing that Enhertu offered better quality of life than the doctors’ choice of chemotherapy

    differences in side effects between Enhertu and chemotherapy
    Released:
    Sep 14, 2022
    Format:
    Podcast episode

    Titles in the series (100)

    Breastcancer.org is a nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer. Our mission is to help women and their loved ones make sense of the complex medical and personal information about breast cancer, so they can make the best decisions for their lives. Breastcancer.org podcasts offer unique insights on prevention, treatment, research, and other breast cancer topics from our medical experts and invited guests.